A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multicenter Study to Evaluate the Efficacy and Safety of Tadalafil Once-Daily Dosing for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia and Erectile Dysfunction
Phase of Trial: Phase III
Latest Information Update: 18 Sep 2019
Price : $35 *
At a glance
- Drugs Tadalafil (Primary) ; Tamsulosin
- Indications Benign prostatic hyperplasia; Erectile dysfunction
- Focus Registrational; Therapeutic Use
- Sponsors Eli Lilly and Company
- 31 Aug 2018 Biomarkers information updated
- 27 Jan 2016 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
- 15 Feb 2015 Planned End Date changed from 1 Mar 2016 to 1 Dec 2015 as reported by ClinicalTrials.gov record.